McMillan Sarah K, Boria Pedro, Moore George E, Widmer William R, Bonney Patty L, Knapp Deborah W
Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN 47907, USA.
J Am Vet Med Assoc. 2011 Oct 15;239(8):1084-9. doi: 10.2460/javma.239.8.1084.
OBJECTIVE-To evaluate the antitumor activity and toxic effects of deracoxib, a selective cyclooxygenase-2 inhibitor, in dogs with transitional cell carcinoma (TCC) of the urinary bladder. DESIGN-Clinical trial. Animals-26 client-owned dogs with naturally occurring, histologically confirmed, measurableTCC of the urinary bladder. PROCEDURES-Dogs were treated PO with deracoxib at a dosage of 3 mg/kg/d (1.36 mg/lb/d) as a single-agent treatment for TCC. Tumor response was assessed via radiography, abdominal ultrasonography, and ultrasonographic mapping of urinary bladder masses. Toxic effects of deracoxib administration in dogs were assessed through clinical observations and hematologic and biochemical analyses. RESULTS-Of 24 dogs for which tumor response was assessed, 4 (17%) had partial remission, 17 (71%) had stable disease, and 3 (13%) had progressive disease; initial response could not be assessed in 2 of 26 dogs. The median survival time was 323 days. Median time to progressive disease was 133 days. Renal, hepatic, and gastrointestinal abnormalities attributed to deracoxib administration were noted in 4% (1/26), 4% (1/26), and 19% (5/26) of dogs, respectively. CONCLUSIONS AND CLINICAL RELEVANCE-Results indicated that deracoxib was generally well tolerated by dogs and had antitumor activity against TCC.
目的——评估选择性环氧化酶-2抑制剂德拉昔布对患有膀胱移行细胞癌（TCC）的犬的抗肿瘤活性和毒性作用。
设计——临床试验。
动物——26只客户拥有的犬，患有自然发生、经组织学证实且可测量的膀胱TCC。
程序——犬口服德拉昔布，剂量为3毫克/千克/天（1.36毫克/磅/天），作为TCC的单药治疗。通过X线摄影、腹部超声检查和膀胱肿块的超声定位评估肿瘤反应。通过临床观察以及血液学和生化分析评估德拉昔布对犬的毒性作用。
结果——在评估肿瘤反应的24只犬中，4只（17%）部分缓解，17只（71%）病情稳定，3只（13%）病情进展；26只犬中有2只无法评估初始反应。中位生存时间为323天。至疾病进展的中位时间为133天。分别在4%（1/26）、4%（1/26）和19%（5/26）的犬中发现了归因于德拉昔布给药的肾脏、肝脏和胃肠道异常。
结论及临床意义——结果表明，犬对德拉昔布总体耐受性良好，且对TCC具有抗肿瘤活性。
